Did you know?
ChinaBio® Group is a consulting and advisory firm helping life science companies and investors achieve success in China. ChinaBio works with U.S., European and APAC companies and investors seeking partnerships, acquisitions, novel technologies and funding in China.
Have the latest stories on China's life science industry delivered to your inbox daily or weekly - free!
Moderna to Open Four Asia Subsidiaries to Expand Reach for mRNA Portfolio
Based on sales of its COVID-19 mRNA vaccine, Moderna announced plans to open subsidiaries in four Asian countries --
In the company's press release, Moderna said it expects the Asia-Pacific region will become an “integral part” of its business. It certainly is a big change for the company, which currently has only 24 employees in
So far, the company has announced plans to build a mRNA vaccine manufacturing facility in
“There’s a few more countries in
Bancel continued, "2021 was a year of impact for Moderna, and I am proud to see continued growth in 2022 as we expand our presence in
Moderna pointed out that
Moderna's growing portfolio in prophylactic vaccines, cardiovascular diseases, oncology, and rare diseases is based on its mRNA technology. The company's pipeline currently consists of 40 development programs, including 25 in clinical trials.
Although Moderna currently is active in only twelve markets globally, more than 70 markets, including
Moderna also laid out its plans for future products built around four strategic pillars:
- Developing a pan-respiratory annual booster vaccine and continuously customizing it. A pan-respiratory annual single booster vaccine covering multiple viruses, such as COVID-19, Flu, and Respiratory Syncytial Virus, would create value for the healthcare system through compliance, convenience to the customer and reduction in vaccine administration cost
- Developing first-in-class vaccines against latent viruses for which there are no approved vaccines today. Latent viruses infect the body, lay dormant, and do not replicate but possess the capacity to activate, causing disease. In addition, new emerging evidence highlights that latent viral infections may have yet unknown negative effects. Moderna has clinical candidates in development for several latent viruses, including Epstein-Barr Virus (Phase 1), human immunodeficiency virus (Phase 1), and Cytomegalovirus (Phase 3)
- Developing therapeutics based on mRNA-encoded proteins across oncology, cardiovascular, auto-immune disorders, and rare genetic diseases
- Developing therapeutics based on mRNA-encoded gene-editing enzymes
According to Moderna, its mRNA platform builds on advances in basic and applied mRNA science, delivery technology and manufacturing. It has developed therapeutics and vaccines for infectious diseases, immuno-oncology, rare diseases, cardiovascular diseases, and auto-immune diseases.
See our other articles on Moderna.